An analysis of the pharmacokinetics of high dose intravenous Melphalan in multiple myeloma.

被引：0
|
作者：
Kalakonda, N [1 ]
Welby-Everard, P [1 ]
Dougal, M [1 ]
Ranson, M [1 ]
Scarffe, JH [1 ]
Chopra, R [1 ]
机构：
[1] Christie Hosp, Dept Haematol & Oncol, Manchester, Lancs, England
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4661
引用
收藏
页码：321B / 321B
页数：1
相关论文
共 50 条
  • [21] EFFECT OF BODY COMPOSITION AND RENAL FUNCTION ON THE PHARMACOKINETICS OF HIGH-DOSE MELPHALAN FOR MULTIPLE MYELOMA
    Vogl, D. T.
    Mick, R.
    Stoopler, E.
    Davis, L. E.
    Paul, T. M.
    Salazar, G.
    Raguza-Lopez, M.
    Porter, D. L.
    Luger, S. M.
    Stadtmauer, E. A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S248 - S248
  • [22] ASCT and high-dose melphalan in multiple myeloma
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2014, 15 (11): : E481 - E481
  • [23] SINGLE-DOSE INTRAVENOUS MELPHALAN IN ADVANCED MULTIPLE-MYELOMA
    BACK, H
    LINDBLAD, R
    RODJER, S
    WESTIN, J
    ACTA HAEMATOLOGICA, 1990, 83 (04) : 183 - 186
  • [24] Outpatient high dose melphalan in multiple myeloma patients
    Medoff, E
    Kassar, M
    Seropian, S
    Cooper, D
    BONE MARROW TRANSPLANTATION, 2005, 35 : S248 - S248
  • [25] High-dose melphalan in patients with multiple myeloma
    Moreau, P
    Le Bonniec, M
    Harousseau, JL
    BULLETIN DU CANCER, 1999, 86 (03) : 283 - 288
  • [26] PHARMACOKINETICS OF ORAL AND INTRAVENOUS MELPHALAN DURING ROUTINE TREATMENT OF MULTIPLE-MYELOMA
    BOSANQUET, AG
    GILBY, ED
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1982, 18 (04): : 355 - 362
  • [27] HIGH-DOSE MELPHALAN FOR MULTIPLE-MYELOMA
    CAVO, M
    BACCARANI, M
    GOBBI, M
    TURA, S
    LANCET, 1983, 2 (8360): : 1194 - 1194
  • [28] MODELING THROMBOCYTOPENIA AS A PREDICTOR OF OUTCOMES FOLLOWING SINGLE, HIGH DOSE MELPHALAN AND STEM CELL TRANSPLANT IN MULTIPLE MYELOMA.
    Irby, D.
    Cottini, F.
    Hade, E.
    Hofmeister, C.
    Phelps, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S120 - S120
  • [29] High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.
    Rossi, Adriana C.
    Monge, Jorge
    Niesvizky, Ruben
    Hsu, Jing Mei
    Shore, Tsiporah
    Van Besien, Koen
    Pearse, Roger
    Mark, Tomer
    Jayabalan, David
    Mayer, Sebastian Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] High dose therapy for multiple myeloma - Getting beyond high dose melphalan
    Giralt, S.
    Oazilbash, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 51 - 52
12345